Program
anbalcabtagene autoleucel
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lupus Nephritis, led by Curocell.
Furthest: phase 2, since Apr 5, 20212 company-led studies, 2 open or runningNext primary completion: Jun 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Curocell | 22 open or running | phase 2since Apr 5, 2021 | Apr 5, 2021 | Jun 2030phase 2 · NCT07364396 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2021First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04836507 · 91 planned · South Korea
- Aug 20, 2025Phase 2 study in Lupus NephritisNCT07364396 · 39 planned
Ahead
- Jun 2030Primary completion: phase 2 study in Lupus NephritisNCT07364396
- Aug 15, 2030Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04836507
TargetBeta
CD19 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07364396Lupus Nephritis | 2 | Not yet recruiting | Jun 2030 | 39 |
| NCT04836507Lymphoma, Large B-Cell, Diffuse · South Korea | 2 | Recruiting | Aug 15, 2030 | 91 |
How it is read
Names in the registry
- “CRC01”, 2 entries
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.